Bellagio Medical: the new era of glaucoma treatment
Bellagio Medical is an innovative start up, focused on the development of a new titratable glaucoma device, the Titran.
Titran. Innovative Medical Devices.
Titran features a single channel with multiple outflow micro-channels, that act as a river delta.
The surgeon chooses to open the filtration holes on the right or on the left aspect of the surface of the innotative Filtering Delta, thus promoting the formation of a filtering bleb on one side of the device or on both. On the surface of the Filtering Delta there are 6 filtration micro-holes, 2 having 20 microns diameter, 2 having 35 microns diameter, 2 having 50 microns. The filtration holes are arranged in two rows, one with decreasing diameter holes and one with increasing diameter holes. This peculiar filtering strategy allows for multiple filtration combinations. A custom-made filtration profile is easily achieved for each and every patient.
Titratable outflow.
The Titratable Filtering Delta System.
Traditional glaucoma surgery, such as trabeculectomy, tubes, valves or MIGS, is a one-size-fits-all procedure, while all glaucoma patients are different. Each patient deserves a custom-made approach, considering the glaucoma stage, medications, previous treaments and conjunctival integrity. Traditional surgery suffers from many sight threatening complications, like post operative hypotony, athalamia, choroidal detachment. It’s a world of unmet needs: surgery has to be tailored for each patient. Titran offers new era of titratable possibilities. Outflow rate can be subsequently increased by the progressive opening of new filtration sites of different diameters, days, months or even years after surgery.
The Company was founded in 2025 by Dr. Paolo Cecchini, MD, PhD and it is based in Milan, Italy. The Titran project won the 2025 iNovation Den at the 43rd Congress of the European Society of Cataract and Refractive Surgeons -ESCRS, held in Copenhagen on the 12th of September, 2025, attracting the interest of many investors and ophtalmic companies.